
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


AbbVie Inc (ABBV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/27/2025: ABBV (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 6.7% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 313.20B USD | Price to earnings Ratio 74.08 | 1Y Target Price 210.01 |
Price to earnings Ratio 74.08 | 1Y Target Price 210.01 | ||
Volume (30-day avg) 6202936 | Beta 0.54 | 52 Weeks Range 148.19 - 216.66 | Updated Date 04/24/2025 |
52 Weeks Range 148.19 - 216.66 | Updated Date 04/24/2025 | ||
Dividends yield (FY) 3.71% | Basic EPS (TTM) 2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-04-25 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 7.59% | Operating Margin (TTM) 36.66% |
Management Effectiveness
Return on Assets (TTM) 8.49% | Return on Equity (TTM) 62.29% |
Valuation
Trailing PE 74.08 | Forward PE 14.29 | Enterprise Value 369002045150 | Price to Sales(TTM) 5.56 |
Enterprise Value 369002045150 | Price to Sales(TTM) 5.56 | ||
Enterprise Value to Revenue 6.55 | Enterprise Value to EBITDA 24.75 | Shares Outstanding 1768979968 | Shares Floating 1761471078 |
Shares Outstanding 1768979968 | Shares Floating 1761471078 | ||
Percent Insiders 0.1 | Percent Institutions 73.81 |
Analyst Ratings
Rating 4 | Target Price 210.93 | Buy 4 | Strong Buy 11 |
Buy 4 | Strong Buy 11 | ||
Hold 11 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AbbVie Inc

Company Overview
History and Background
AbbVie Inc. was founded in 2013 when it separated from Abbott Laboratories. It has grown through internal research and development and strategic acquisitions, focusing on developing and marketing innovative pharmaceuticals.
Core Business Areas
- Immunology: Focuses on treatments for autoimmune diseases like rheumatoid arthritis and Crohn's disease. Key product: Humira (biosimilars now affecting sales), Skyrizi, Rinvoq.
- Oncology: Develops therapies for various cancers, including hematological malignancies and solid tumors. Key products: Imbruvica, Venclexta.
- Neuroscience: Focuses on treatments for neurological and psychiatric disorders. Key products: Botox Therapeutic, Ubrelvy.
- Aesthetics: Offers a range of aesthetic products including Botox Cosmetic, Juvederm dermal fillers. Competitors include Galderma and Merz Pharma.
Leadership and Structure
AbbVie is led by CEO Richard A. Gonzalez. The organizational structure is divided into research and development, commercial operations, and support functions.
Top Products and Market Share
Key Offerings
- Humira: A biologic drug used to treat autoimmune diseases. Once a blockbuster, its revenue has declined due to biosimilar competition. Revenue peaked around $20 billion annually. Competitors: Biosimilars from Amgen (AMGN), Novartis (NVS), and others; alternative treatments from J&J (JNJ), Eli Lilly (LLY), and others.
- Skyrizi: A biologic used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Growing rapidly. Aiming to offset Humira revenue loss. Competitors: J&J's Stelara, Novartis' Cosentyx, Eli Lilly's Taltz.
- Rinvoq: An oral JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. Also a key growth driver. Competitors: Pfizer's Xeljanz, Eli Lilly's Olumiant.
- Imbruvica: A cancer drug used to treat blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia. Competitors: AstraZeneca's Calquence, BeiGene's Brukinsa.
- Botox Cosmetic/Therapeutic: Botulinum toxin used for cosmetic and therapeutic purposes. Competitors: Galderma's Dysport, Merz Pharma's Xeomin.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulations, and patent protection. Trends include personalized medicine, gene therapy, and digital health.
Positioning
AbbVie is a major player in the pharmaceutical industry, known for its strong presence in immunology, oncology, and neuroscience. Its competitive advantage lies in its innovative pipeline and global commercial infrastructure.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be worth over $1 trillion. AbbVie is positioned to capture a significant portion of this market through its diversified portfolio and pipeline, potentially addressing $200-$300 billion across its therapeutic areas.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust R&D pipeline
- Global commercial presence
- High profit margins
- Experienced management team
Weaknesses
- Reliance on Humira (decreasing)
- Patent expiration risk
- High debt levels (from acquisitions)
- Exposure to biosimilar competition
- Pricing pressure
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- Growth in emerging markets
- Development of innovative therapies
- Partnerships and collaborations
Threats
- Increasing competition
- Regulatory changes
- Economic downturns
- Patent challenges
- Biosimilar erosion
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- BMY
- LLY
- NVS
Competitive Landscape
AbbVie faces intense competition from other major pharmaceutical companies. AbbVie has a strong presence in immunology and oncology, while competitors have strengths in other areas.
Major Acquisitions
Allergan
- Year: 2020
- Acquisition Price (USD millions): 63000
- Strategic Rationale: Acquisition of Allergan diversified AbbVie's product portfolio and reduced reliance on Humira. It added aesthetics (Botox), women's health, and other therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: AbbVie's growth has been driven by Humira and other key products. Growth has slowed with biosimilar competition.
Future Projections: Analyst estimates vary, but generally project continued growth driven by Skyrizi, Rinvoq, and other pipeline products.
Recent Initiatives: Recent strategic initiatives include acquisitions (e.g., Allergan) and investments in R&D to expand the product portfolio.
Summary
AbbVie is a major pharmaceutical company with a strong presence in immunology, oncology, and neuroscience. Its growth has been historically driven by Humira, but it is now diversifying its portfolio to offset biosimilar competition. Strategic acquisitions like Allergan have expanded its reach, but high debt levels remain a concern. AbbVie's continued success depends on its ability to innovate and bring new products to market.
Similar Companies

BMY

Bristol-Myers Squibb Company



BMY

Bristol-Myers Squibb Company

JNJ

Johnson & Johnson



JNJ

Johnson & Johnson

LLY

Eli Lilly and Company



LLY

Eli Lilly and Company

MRK

Merck & Company Inc



MRK

Merck & Company Inc

NVS

Novartis AG ADR



NVS

Novartis AG ADR

PFE

Pfizer Inc



PFE

Pfizer Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AbbVie Inc
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 2013-01-02 | CEO & Director Mr. Robert A. Michael CPA | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 55000 | Website https://www.abbvie.com |
Full time employees 55000 | Website https://www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.